WHAT’S NEW IN METASTATIC COLON CANCER TREATMENT?
In this review, we present the current innovations in the field of metastatic colon cancer (mCRC). Tumor placement is important in the mCRC treatment decision, and KRAS, NRAS, BRAF mutation analysis is performed in terms of prognosis/predictivity. Immunotherapy is the treatment option in patients wi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Istanbul University Press
2021-07-01
|
| Series: | İstanbul Tıp Fakültesi Dergisi |
| Subjects: | |
| Online Access: | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/0712313B37E546E288D2757893803070 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850034736655761408 |
|---|---|
| author | Senem Karabulut Mehmet Karabulut Didem Taştekin |
| author_facet | Senem Karabulut Mehmet Karabulut Didem Taştekin |
| author_sort | Senem Karabulut |
| collection | DOAJ |
| description | In this review, we present the current innovations in the field of metastatic colon cancer (mCRC). Tumor placement is important in the mCRC treatment decision, and KRAS, NRAS, BRAF mutation analysis is performed in terms of prognosis/predictivity. Immunotherapy is the treatment option in patients with 5-6% and dMMR/MSI. The concept of NeoRAS will become more on the agenda in the near future as high-level evidence becomes available. Molecular evaluations have become extremely important in terms of prognosis and predictions in the treatment of mCRC, as in many tumors today |
| format | Article |
| id | doaj-art-0b8b47e072e14bb3916798a20de2d232 |
| institution | DOAJ |
| issn | 1305-6441 |
| language | English |
| publishDate | 2021-07-01 |
| publisher | Istanbul University Press |
| record_format | Article |
| series | İstanbul Tıp Fakültesi Dergisi |
| spelling | doaj-art-0b8b47e072e14bb3916798a20de2d2322025-08-20T02:57:43ZengIstanbul University Pressİstanbul Tıp Fakültesi Dergisi1305-64412021-07-0184342542910.26650/IUITFD.2020.0086123456WHAT’S NEW IN METASTATIC COLON CANCER TREATMENT?Senem Karabulut0https://orcid.org/0000-0003-4740-9973Mehmet Karabulut1https://orcid.org/0000-0002-1889-5637Didem Taştekin2https://orcid.org/0000-0002-9522-9849İstanbul Üniversitesi, İstanbul, TürkiyeSağlık Bilimleri Üniversitesi, Istanbul, Turkiyeİstanbul Üniversitesi, İstanbul, TürkiyeIn this review, we present the current innovations in the field of metastatic colon cancer (mCRC). Tumor placement is important in the mCRC treatment decision, and KRAS, NRAS, BRAF mutation analysis is performed in terms of prognosis/predictivity. Immunotherapy is the treatment option in patients with 5-6% and dMMR/MSI. The concept of NeoRAS will become more on the agenda in the near future as high-level evidence becomes available. Molecular evaluations have become extremely important in terms of prognosis and predictions in the treatment of mCRC, as in many tumors todayhttps://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/0712313B37E546E288D2757893803070metastatic colon cancertreatmentinnovations |
| spellingShingle | Senem Karabulut Mehmet Karabulut Didem Taştekin WHAT’S NEW IN METASTATIC COLON CANCER TREATMENT? İstanbul Tıp Fakültesi Dergisi metastatic colon cancer treatment innovations |
| title | WHAT’S NEW IN METASTATIC COLON CANCER TREATMENT? |
| title_full | WHAT’S NEW IN METASTATIC COLON CANCER TREATMENT? |
| title_fullStr | WHAT’S NEW IN METASTATIC COLON CANCER TREATMENT? |
| title_full_unstemmed | WHAT’S NEW IN METASTATIC COLON CANCER TREATMENT? |
| title_short | WHAT’S NEW IN METASTATIC COLON CANCER TREATMENT? |
| title_sort | what s new in metastatic colon cancer treatment |
| topic | metastatic colon cancer treatment innovations |
| url | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/0712313B37E546E288D2757893803070 |
| work_keys_str_mv | AT senemkarabulut whatsnewinmetastaticcoloncancertreatment AT mehmetkarabulut whatsnewinmetastaticcoloncancertreatment AT didemtastekin whatsnewinmetastaticcoloncancertreatment |